| Q40579192 | Clinical pharmacokinetics of paclitaxel |
| Q36079535 | Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. |
| Q34307126 | Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors |
| Q35122772 | Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery |
| Q41701150 | Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). |
| Q37892098 | Intestinal lymphatic transport for drug delivery |
| Q41052675 | Multidrug resistance in cancer chemotherapy |
| Q37714557 | Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity |
| Q37318921 | Optimization of Paclitaxel Containing pH-Sensitive Liposomes By 3 Factor, 3 Level Box-Behnken Design |
| Q40397088 | Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer |
| Q28728340 | Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo |
| Q33187648 | Pharmacological effects of formulation vehicles : implications for cancer chemotherapy |
| Q33182080 | Role of formulation vehicles in taxane pharmacology |